Key Takeaways CRSP gained 14% in a month, driven by positive CTX310 in vivo gene therapy trial data. Casgevy, its approved ex vivo gene therapy, saw Q1 sales rise to $14.2M with 65 treatment centers activated. CRSP expects multiple pipeline updates in 2025, including early data for CTX320 and new in vivo programs.Shares of CRISPR Therapeutics (CRSP) have risen 14% over the past month, likely driven by encouraging results from the first candidates in its in vivo pipeline.CRSP’s Positive In Vivo Therapy Dat ...